Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/1Yn3OXXEH6 https://t.co/HmQiYFSQMU

Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096

The 2025 Rheumatology Year in Review The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/71stL3X8my

ANAs and Autoantibodies https://t.co/AANvCKeAl0 https://t.co/SSPUxMEuLh

Are JAK Inhibitors Better at Pain Relief in RA? Among rheumatoid arthritis (RA) patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial https://t.co/QrbwlxIm3d

Review of Restless Legs Syndrome JAMA has published a full review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia. https://t.co/lPSMH3v7xS https://t.co/lbSfeNrfLz

Acupuncture in SpA metanalysis of 35 RCTs (2,591 AS pts) showed statistically significant improvements BASDAI score, BASFI score, ASDAS, VAS score, CRP level, and ESR level. Findings imited by high heterogeneity & the lack of large-scale, high-quality RCTs. https://t.co/gznAiNo0k4

Retrospective real-world study of 87 Behcets dz pts & inital Rx w/ IFX (n 45) or ADA (n 42) (2020 to 2025) & >60% were on AZA. Complete remission achieved in 76% (IFX) vs 79% (ADA) initially, & 89% vs 77% last visit. Same Rx retention but more relapses w/ IFX (38% v 17%) https://t.co/6FiuYe0GI9

Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf

French Retrospective study (2011-22) of 36129 adult psoriasis pts on biologics who recv antibiotics (9366/26% @ baseline, 61% during FU). Abx treatment assoc w/ 12% greater risk biologic D/C (HR 1.12); more for multiple Abx courses (HR 1.29; 95% CI, 1.24-1.35) https://t.co/2Jv5xCibyd

Congratulations to Lupus Research Alliance 2025 Global Science Award Recipients 1) Drs. Deepak Rao & Alexandra-Chloe Villani at Harvard affiliates; & 2) Dr. Caroline Jefferies at Cedars-Sinai. Grants will support interdisciplinary, collaborative, & synergistic projects in SLE https://t.co/GcfuEty75b